Crick — Clinical Intelligence Platform

Early research (Phase 1)Looking for participantsNCT07619599

What this trial is testing

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Who this might be right for

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainOligoprogressive Lung Non-Small Cell Carcinoma+1 more

City of Hope Medical Center 6

Results for “Oligoprogression”

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Stereotactic Magnetic Resonance Guided Radiation Therapy

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (310 Gy) to the Historical Single-dose Radiosurgery (120 to 25 Gy) With Medico-economic Evaluation.

SMC Radiation Oncology SABR Cohort for Oligometastasis

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

CtDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

Results for “Oligoprogression”

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Stereotactic Magnetic Resonance Guided Radiation Therapy

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

SMC Radiation Oncology SABR Cohort for Oligometastasis

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

CtDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (310 Gy) to the Historical Single-dose Radiosurgery (120 to 25 Gy) With Medico-economic Evaluation.